Abstract
The uraemic syndrome is characterized by a deterioration of biochemical and physiologic functions, in parallel with the progression of renal failure, and results in important but variable symptomatology. Although well known for more than 160 years (1), our knowledge about the responsible factors remains inconsistent and incomplete. The quest for βtheβ uraemic toxin has been overemphasized, not taking into account the uraemic syndrome as the result of a cumulative retention of innumerable compounds. The extrapolation of in vitro data to the clinical situation has sometimes resulted in incorrect hypotheses, whereas trivial factors with a potential bias on the results have not been taken into account
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Prevost JL, Dumas JA: Examen du sang et de son action dans les divers phénomènes de la vie. Ann Chimie et Physiol 23: 90, 1821
Lazarus JM, Lowrie EG, Hampers CL, Merrill P: Cardiovascular disease in uremic patients on hemodialysis. Kidney Int 7: S167, 1975
Wray TM, Stone WJ: Uremic pericarditis: a prospective echocardiographic and clinical study. Clin Nephrol 6: 295, 1976
Parfrey PS, Harnett JD, Barre PE: The natural history of myocardial disease in dialysis patients. J Am Soc Nephrol 2: 2, 1991
Parfrey PS, Harnett JD, Griffiths SM, Gault MH, BarrΓ© PE: Congestive heart failure in dialysis patients. Arch Intern Med 148: 1519, 1988.
Rostand SG, Sanders C, Kirk KA, Rutsky EA, Fraser RG: Myocardial calcification and cardiac dysfunction in chronic renal failure. Am J Med 85: 651, 1988
Lindner A, Kenny M, Meacham A: Effects of a circulating factor in patients with essential hypertension on intracellular free calcium in normal platelets. N Engl J Med 316:509, 1987
Mason MF, Resnik H, Minot AS, Rainey J, Pitcher C, Harrison TR: Mechanism of experimental uremia. Arch Intern Med 60: 312, 1937
Raab W: Cardiotoxic substance in the blood and heart muscle in uremia. J Lab Clin Med 29: 715, 1944
Rambausek M, Mann JFE, Mall G, Kreusser W, Ritz E: Cardiac findings in experimental uremia. Contr Nephrol 52: 125, 1986
Kong CH, Thompson FD: Hemodynamic responses to head-up tilt in uremic patients. Clin Nephrol 33: 283, 1990
Meggs LG, Ben-Ari J, Gammon D, Choudhury M, Goodman AI: Effect of chronic uremia on the cardiovascular alpha receptor. Life Sciences 39: 169, 1986
Mall G, Rambausek M, Neumeister A, Kollmar S, Vetterlein F, Ritz E: Myocardial interstitial fibrosis in experimental uremia β implications for cardiac compliance. Kidney Int 33: 804, 1988
Kramer W, Wizemann V, Kinder M, Thormann J: UrΓ€mische Herzkrankheit: Inzidenz und Klinische Wertigkeit nicht-invasiver kardialer Befunde bei dialy-sepflichtiger Niereninsuffizienz. Med Welt 36: 1228, 1985
Fraser CL, Arieff AI: Nervous system complications in uremia. Ann Inter Med 109: 143, 1988
Vanholder RC: Neuropsychiatric alterations in uraemia, in Oxford Textbook of Clinical Nephrology, edited by Cameron S, Davison AM, GrΓΌnfeld JP, Kerr DS, Ritz E, Oxford University Press, Oxford, 1992, p 1396
Kimmel PL, Miller G, Mendelson WB: Sleep apnea syndrome in chronic renal disease. Am J Med 86: 308, 1989
Shvili Y, Gafter U, Zohar Y, Talmi YP, Levi J: Brainstem auditory evoked responses in rats with experimental renal failure. Clin Science 76: 415, 1989
Braguer D, Gallice P, Yatzidis H, Berland Y, Crevat A: Restoration by biotin of the in vitro microtubule formation inhibited by uremic toxins. Nephron 57: 192, 1991
Eschbach JW, Kelly MR, Haley NR, Abels RI, Adamson JW: Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med 321: 158, 1989
Bogin E, Massry SG, Levi J, Djaldetti M, Bristol G, Smith J: Effect of parathyroid hormone on osmotic fragility of human erythrocytes. J Clin Invest 69: 1017, 1982
Pavlovic-Kentera V, Clemons GK, Djukanovic L, Biljanovic-Paunovic L: Erythropoietin and anemia in chronic renal failure. Exp Hematol 15: 785, 1987
Radtke HW, Rege AB, La Marche MB, Bartos D, Bartos F, Campbell RA, Fischer JW: Identification of spermine as an inhibitor of erythropoiesis in patients with chronic renal failure. J Clin Invest 67: 1623, 1981
Segal GM, Stueve T, Adamson JW: Spermine and spermidine are non-specific inhibitors of in vitro hematopoiesis. Kidney Int 31: 72, 1987
Kushner D, Beckman B, Nguyen L, Chen S, Della Santina C, Husserl F, Rice J, Fisher JW: Polyamines in the anemia of end-stage renal disease. Kidney Int 39: 725, 1991
UreΓ±a P, Bonnardeaux A, Eckardt KU, Kurtz A, DrΓΌeke TB: Insulin-like growth factor I: a modulator of erythropoiesis in uraemic patients? Nephrol Dial Transplant 7: 40, 1992
Larsson SO: On coagulation and fibrinolysis in renal failure. Scand J Haematol 15(Suppl): 1, 1971
Remuzzi G: Bleeding in renal failure. Lancet 1: 1205, 1988
Noris M, Benigni A, Boccardo P, Aiello S, Gaspari F, Todeschini M, Figliuzzi M, Remuzzi G: Enhanced nitric oxide synthesis in uremia: implications for platelet dysfunction and dialysis hypotension. Kidney Int 44: 445, 1993
Remuzzi G, Livio M, Marchiaro G, Mecca G, de Gaetano MG: Bleeding in renal failure: altered platelet function in chronic uraemia only partially corrected by haemodialysis. Nephron 22: 347, 1978
Di Minno G, Cerbone A, Usberti M, Cianciaruso B, Cortese A, Farace MJ, Martinez J, Murphy S: Platelet dysfunction in uremia. II. Correction by arachidonic acid of the impaired exposure of fibrinogen receptors by adenosine diphosphate or collagen. J Lab Clin Med 108: 246, 1986
Remuzzi G, Benigni A, Dodesini P, Schieppati A, Livio M, De Gaetano G, Day JS, Smith WL, Pinca E, Patrignani P, Patrono C: Reduced platelet thromboxane formation in uremia. Evidence for a functional cyclo-oxygenase defect. J Clin Invest 71: 762, 1983
Tison P, Cernacek P, Silvanova E, DzΓΊrik R: Uremic βtoxinsβ and blood platelet carbohydrate metabolism. Nephron 28: 192, 1981
Holloway DS, Vagher JP, Caprini JA, Simon NM, Mockros LF: Thrombelastography of blood from subjects with chronic renal failure. Thromb Res 45: 817, 1987
Warren RP, Hultin MB, Coller BS: Increased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in renal failure. Am J Med 66: 226, 1979
Vanholder R, Ringoir S: Infectious morbidity and defects of phagocytic function in end-stage renal disease: a review. J Am Soc Nephrol 3: 1541, 1993
Goldblum SE, Reed WP: Host defenses and immunologic alterations associated with chronic hemodialysis. Ann Int Med 93: 597, 1980
Lewis SL, Van Epps DE: Neutrophil and monocyte alterations in chronic dialysis patients. Am J Kidney Dis 9: 381, 1987
Ponassi A, Morra L, Gurreri G, Moccia F, Giusti M, Caristo G, Sacchetti C: Alterations of granulopoiesis in chronic uremic patients treated with intermittent hemodialysis. Acta Haematol 77: 220, 1987
Vanholder R, Ringoir S, Dhondt A, Hakim R: Phagocytosis in uremic and hemodialysis patients: a prospective and cross sectional study. Kidney Int 39: 320, 1991
Vanholder R, Ringoir S: Polymorphonuclear cell function and infection in dialysis. Kidney Int 38: S91, 1992
Vanholder R, Van Biesen W, Ringoir S: Contributing factors to the inhibition of phagocytosis in hemodialyzed patients. Kidney Int 44: 208, 1993
Schena FP, Pertosa G: Fibronectin and the kidney. Nephron 48: 177, 1988
Flament J, Goldman M, Waterlot Y, Dupont E, Wybran J, Vanherweghem JL: Impairment of phagocyte oxidative metabolism in hemodialyzed patients with iron overload. Clin Nephrol 25: 227, 1986
Veys N, Vanholder R, Ringoir S: Correction of deficient phagocytosis during erythropoietin treatment in maintenance hemodialysis patients. Am J Kidney Dis 19: 358, 1992
HΓΆrl WH, Haag-Weber M, Georgopoulos A, Block LH: Physicochemical characterization of a polypeptide present in uremic serum that inhibits the biological activity of polymorphonuclear cells. Proc Natl Acad Sci USA 87: 6353, 1990
Haag-Weber M, Mai B, HΓΆrl WH: Isolation of a granulocyte inhibitory protein in uremia: homology to beta2microglobulin. Nephrol Dial Transplant 9: 382, 1994
Keane WF, Maddy MF: Host defense and infectious complications in maintenance hemodialysis patients, in Replacement of Renal Function by Dialysis, edited by Maher JF, Kluwer Academic Publishers, Dordrecht, 1989, p 865
Raskova J, Ghobrial I, Czerwinski DK, Shea SM, Eisinger RP, Raska K: B-cell activation and immunoregulation in end-stage renal disease patients receiving hemodialysis. Arch Int Med 147: 89, 1987
Langhoff E, Ladefoged J, Odum N: Effect of inteleukin-2 and methylprednisolone on in vitro transformation of uremic lymphocytes. Int Arch Allergy Applied Immunol 81:5, 1986
Asaka M, Iida H, Izumino K, Sasayama S: Depressed natural killer cell activity in uremia. Nephron 49: 291, 1988
Ladefoged J, Langhoff E: Accessory cell functions in mononuclear cell cultures from uremic patients. Kidney Int 37: 126, 1990
Hershkovitz R, Rathaus M, Mekori YA, Lider O, Bernheim J: Uraemic serum inhibits peripheral blood rnononuclear cell and purified T-cell adhesion to extracellular matrix glycoproteins. Nephrol Dial Transplant 8: 951, 1993 (Abstract)
Girndt M, KΓΆhler H, Schiedhelm-Weick E, Meyer zum BΓΌschenfelde KH, Fleischer B: T cell activation defect in hemodialysis patients: evidence for a role of the B7/CD28 pathway. Kidney Int 44: 359, 1993
Baliga R, George VT, Ray PE, Holliday MA: Effects of reduced renal function and dietary protein on muscle protein synthesis. Kidney Int 39: 831, 1991
Mak RHK, DeFronzo RA: Glucose and insulin metabolism in uremia. Nephron 61: 377, 1992
De Fronzo RA, Andres R, Edgar P, Walker WG: Carbohydrate metabolism in uremia: a review. Medicine (Baltimore) 52: 469, 1973
Cecchin F, Ittoop O, Sinha MK, Caro JF: Insulin resistance in uremia: insulin receptor kinase activity in liver and muscle from chronic uremic rats. Am J Physiol 254: E394, 1988
Schmitz O, Amfred J, Orskov L, Hother Nielsen O, Orskov H, Posborg V: Influence of hyperglycemia on glucose uptake and hepatic glucose production in non-dialyzed uremic patients. Clin Nephrol 30: 27, 1988
Jacobs DB, Hayes GR, Truglia JA, Lockwood DH: Alterations of glucose transporter systems in insulin-resistant uremic rats. Am J Physiol 257: E193, 1989
Mak RHK: Intravenous 1,25 dihydrocholecalciferol corrects glucose intolerance in hemodialysis patients. Kidney Int 41: 1049, 1992
MacCaleb ML, Izzo MS, Lockwood DH: Characterization and partial purification of a factor from uremic human serum that induces insulin resistance. J Clin Invest 75: 391, 1985
DzΓΊrik R, SpustovΓ‘ V, Gerykova M: Pathogenesis and consequences of the alteration of glucose metabolism in renal insufficiency, in Uremic Toxins, edited by Ringoir S, Vanholder R, Massry SG, Plenum Press, New York, 1987, p 105
DzΓΊrik R. SpustovΓ‘ V, LajdovΓ‘ I: Inhibition of glucose utilization in isolated rat soleus muscle by pseudouridine: implications for renal failure. Nephron 65: 108, 1993
Fadda GZ, Akmal M, Premdas FH, Lipson LG, Massry SG: Insulin release from pancreatic islets: effects of CRF and excess PTH. Kidney Int 33: 1066, 1988
Katz AI, Emmanouel DS: Metabolism of polypeptide hormones by the normal kidney and in uremia. Nephron 22: 69, 1978
Kalk WJ, Morley JE, Gold CH, Meyers A: Thyroid function tests in patients on regular hemodialysis. Nephron 25: 173, 1980
Elias AN, Vaziri ND, Pandian MR, Iyer K, Ansari MA: Dopamine and TSH secretion in uremic male rats. Hormone Res 27: 102, 1987
Lippe B, Fine RN, Koch VH, Sherman BM: Accelerated growth following treatment of children with chronic renal failure with recombinant human growth hormone (Somatrem): a preliminary report. Acta Paed Scand 343(Suppl): 127, 1988
Ziegler TR, Lazarus JM, Young LS, Hakim R, Wilmore DW: Effects of recombinant human growth hormone in adults receiving maintenance hemodialysis. J Am Soc Nephrol 2: 1130, 1993
Chan W, Valerie KC, Chan JCM: Expression of insulin-like growth factor-1 in uremic rats: growth hormone resistance and nutritional intake. Kidney Int 43: 790, 1993
Bommer J: Sexual dysfunction in chronic renal failure. in Oxford Textbook of Clinical Nephrology, edited by Cameron S, Davison AM, Grunfeld JP, Kerr D, Ritz E, Oxford University Press, Oxford, 1992, p 1329
Biasioli S, Mazzali A, Foroni R, DβAndrea G, Feriani M, Chiaramonte S, Cesaro A, Micieli G: Chronobiological variations of prolactin (PRL) in chronic renal failure. Clin Nephrol 30: 86, 1988
Schaefer F, Stanhope R, Scheil H, SchΓΆnberg D, Preece MA, SchΓ€rer K: Pulsatile gonadotropin secretion in pubertal children with chronic renal failure. Acta Endocrin 120: 14, 1989
Ritz E, Matthias S, Seidel A, Reichel H, Szabo A, HΓΆrl WH: Disturbed calcium metabolism in renal failure β pathogenesis and therapeutic strategies. Kidney Int 42: S37, 1992
Andress DL, Pandian MR, Endres DB, Kopp JB: Plasma insulin-like growth factors and bone formation in uremic hyperparathyroidism. Kidney Int 36: 471, 1989
Phillips LS, Fusco AC, Unterman TG, Del Greco F: Somatomedin inhibitor in uremia. J Clin Endocrinol Metab 59: 764, 1984
Andress DL, Howard GA, Birnbaum RS: Identification of a low molecular weight inhibitor of osteobast mitogenesis in uremic plasma. Kidney Int 39: 942, 1991
Hsu CH, Patel SR, Young EW: Mechanism of decreased calcitriol degradation in renal failure. Am J Physiol 262: F192, 1992
Ponticelli C, Bencini PL: Uremic pruritus: a review. Nephron 60: 1, 1992
Motojima M, Nishijima F, Ikoma M, Kawamura T, Yoshioka T, Fogo AB, Sakai T, Ichikawa I: Role for uremic toxins in the progressive loss of intact nephrons in chronic renal failure. Kidney Int 40: 461, 1991
Bonomini V, Feletti C, Stefoni S, Vangelista A: Early dialysis and renal transplantation. Nephron 44: 267, 1986
Vanholder R, DellβAquila R, Jacobs V, Dhondt A, Veys N, Waterloos MA, Van Landschoot N, Van Biesen W, Ringoir S: Depressed phagocytosis in hemodialyzed patients: in vivo and in vitro mechanisms. Nephron 63: 409, 1993
Vanholder R, Hoenich N, Ringoir S: Morbidity and mortality of central venous catheter hemodialysis: a review of 10 yearβs experience. Nephron 47: 274, 1987
Piraino B, Bemardini J, Sorkin M: Catheter infections as a factor in the transfer of continuous ambulatory peritoneal dialysis. Am J Kidney Dis 13: 365, 1989
Duwe AK, Vas SI, Weatherhead JW: Effects of the composition of peritoneal dialysis fluid on chemiluminescence, phagocytosis, and bactericidal activity in vitro. Infect Immun 33: 130, 1981
JΓΆrres A, Topley N, Steenweg L, MΓΌller C, KΓΆttgen E, Gahl GM: Inhibition of cytokine synthesis by peritoneal dialysate persists throughout the CAPD cycle. Am J Nephrol 12: 80, 1992
Vanholder R, Lameire N, Waterloos MA, Van Landschoot N, De Smet R, Vogeleere P, Ringoir S: Depression of PMNL-response to phagocytic challenge in the presence of CAPD-effluent. J Am Soc Nephrol 4: 419, 1993 (Abstract)
Ringoir S, Schoots A, Vanholder R: Uremic toxins. Kidney Int 33: S4, 1988
Vanholder RC, Ringoir SMG: The uraemic syndrome, in Oxford Textbook of Clinical Nephrology, edited by Cameron S, Davison AM, Grunfeld JP, Kerr D, Ritz E, Oxford University Press, Oxford, 1992, p 1236
Boero R, Guarena C, Berto IM, Deabate MC, Rosati C, Quarello F, Piccoli G: Erythrocyte Na, K pump activity and arterial hypertension in uremic dialyzed patients. Kidney Int 34: 691, 1988
Gallice P, Monti JP, Baz M, Murisasco A, Crevat A: 23Na Nuclear magnetic resonance study of Na+, K+ pump inhibition by a fraction from uremic toxins. Clin Chem 34: 2044, 1988
Aparicio M, Vincendeau P, Combe C, Caix J, Gin H, de Precigout V, Bezian JH, Bouchet JL, Potaux L: Improvement of leucocytic Na+K+ pump activity in uremic patients on low protein diet. Kidney Int 40: 238, 1991
Deray G, Pernollet MG, Devynck MA, Zingraff J, Touam A, Rosenfeld J, Meyer P: Plasma digitalis-like activity in essential hypertension or end-stage renal disease. Hypertension 8: 632, 1986
Druml W, Kelly A, May RC, Mitch WE: Abnormal cation transport in uremia. Mechanisms in adipocytes and skeletal muscle from uremic rats. J Clin Invest 81: 1197, 1988
Seth RK, Saini AS, Aggarwal SK: Glutathione peroxidase activity and reduced glutathione content in erythrocytes of patients with chronic renal failure. Scand J Haematol 35: 201, 1985
Costagliola C, Romano L, Sorice P, Di Benedetto A: Anemia and chronic renal failure: the possible role of the oxidative state of glutathione. Nephron 52: 11, 1989
BergstrΓΆm J, Alvestrand A, FΓΌrst P: Plasma and muscle free amino acids in maintenance hemodialysis patients without protein malnutrition. Kidney Int 38: 108, 1990
Fadda GZ, Hajjar SM, Perna AF, Zhou XJ, Lipson LG, Massry SG: On the mechanism of impaired insulin secretion in chronic renal failure. J Clin Invest 87: 255, 1991
Raine AEG, Bedford L, Simpson AWM, Ashley CC, Brown R, Woodhead JS, Ledingham JGG: Hyperparathyroidism, platelet intracellular free calcium and hypertension in chronic renal failure. Kidney Int 43: 700, 1993
Alexiewicz JM, Smogorzewski M, Fadda GZ, Massry SG: Impaired phagocytosis in dialysis patients: studies on mechanisms. Am J Nephrol 11: 102, 1991
Gafter U, Malachi T, Barak H, Levi J: Red blood cell calcium level in chronic renal failure: effect of continuous ambulatory peritoneal dialysis. J Lab Clin Med 116: 386, 1990
Lindner A, Gagne ER, Zingraff J, Jungers P, DrΓΌeke T, Hannaert P, Garay R: A circulating inhibitor of the RBC membrane calcium pump in chronic renal failure. Kidney Int 42: 1328, 1992
Thompson CH, Kemp GJ, Taylor DJ, Ledingham JGG, Radda GK, Rajagopalan B: Effect of chronic uraemia on skeletal muscle metabolism in man. Nephrol Dial Transplant 8:218, 1993
Durozard D, Pimmel P, Baretto S, Caillette A, Labeeuw M, Baverel G, Zech P: 31P NMR spectroscopy investigation of muscle metabolism in hemodialysis patients. Kidney Int 43: 885, 1993
PazmiΓ±o P, Rogoff F, Weinshilboum R: Inhibition of human erythrocyte phenol-O-methyltransferase in uremia. Clin Pharmacol Ther 26: 464, 1979
Depner TA: Suppression of tubular anion transport by an inhibitor of serum protein binding in uremia. Kidney Int 20:511, 1981
Gharib N, Gao CY, Areas JL, El Zein M, Preuss HG: Correlation of renal organic anion and cation transport with blood pressure in SHR. Clin Nephrol 36: 87, 1991
Hsu CH, Patel SR, Young EW, Simpson RU: Production and degradation of calcitriol in renal failure rats. Am J Physiol 253: F1015, 1987
Hsu CH, Patel SR, Young EW, Simpson RU: Production and metabolic clearance of calcitriol in acute renal failure. Kidney Int 33: 530, 1988
Hsu CH, Patel S: Factors influencing calcitriol metabolism in renal failure. Kidney Int 37: 44, 1990
Hsu CH, Vanholder R, Patel S, De Smet RR, Sandra P, Ringoir SMG: Subfractions in uremic plasma ultrafiltrate inhibit calcitriol metabolism. Kidney Int 40: 868, 1991
Hsu CH, Patel SR, Young EW, Vanholder R: Effects of purine derivatives on calcitriol metabolism in rats. Am J Physiol 260: F596, 1991
Hsu CH, Patel SR, Vanholder R: Mechanism of decreased intestinal calcitriol receptor concentration in renal failure. Am J Physiol 264: F662, 1993
Malachi T, Zevin D, Gafter U, Chagnac A, Slor H, Levi J: DNA repair and recovery of RNA synthesis in uremic patients. Kidney Int 44: 385, 1993
Piafsky KM: Disease-induced changes in the plasma binding of basic drugs. Clin Pharmacokin 5: 246, 1980
Lindup WE, Bishop KA, Collier R: Drug binding defect of uraemic plasma: contribution of endogenous binding inhibitors, in Protein Binding and Drug Transport, edited by Tillement JP, Lindenlaub E, Schattauer Verlag, Stuttgart, 1986, p 397
Roman S, Gulyassy PF, Depner TA: Inhibition of salicylate binding to normal plasma by extracts of uremic fluids. Am J Kidney Dis 4: 153, 1984
Vanholder R, Van Landschoot N, De Smet R, Schoots A, Ringoir S: Drug protein binding in chronic renal failure: evaluation of nine drugs. Kidney Int 33: 996, 1988
Vanholder R, De Smet R, Ringoir S: Factors influencing drug protein binding in patients with end stage renal failure. Eur J Clin Pharmacol 44: S17, 1993
MacNamara PJ, Lalka D, Gibaldi M: Endogenous accumulation products and serum protein binding in uremia. J Lab Clin Med 98: 730, 1981
Gulyassy PF, Bottini AT, Stanfel LA, Jarrad EA, Depner TA: Isolation and chemical identification of inhibitors of plasma ligand binding. Kidney Int 30: 391, 1986
Mabuchi H, Nakahashi H: Profiling of endogenous ligand solutes that bind to serum proteins in sera of patients with uremia. Nephron 43: 110, 1986
Mabuchi H, Nakahashi H: Isolation and characterization of an endogenous drug-binding inhibitor present in uremic serum. Nephron 44: 277, 1986
Niwa T, Takeda N, Maeda K, Shibata M, Taternatsu A: Accumulation of furancarboxylic acids in uremic serum as inhibitors of drug binding. Clin Chim Acta 173: 127, 1988
Vanholder R, Hoefliger N, De Smet R, Ringoir S: Extraction of protein bound ligands from azotemic sera: comparison of 12 deproteinization methods. Kidney Int 41: 1707, 1992
Dengler TJ, Robertz-Vaupel GM, Dengler HJ: Albumin binding in uraemia: quantitative assessment of inhibition by endogenous ligands and carbamylation of albumin. Eur J Clin Pharmacol 43: 491, 1992
Paxton JW: Alpha 1-acid glycoprotein and binding of basic drugs. Meth Findings Exp Clin Pharmacol 5: 635, 1983
Nicot G, Charmes JP, Lachatre G, Sautereau D, Valette JP, Eichler B, Leroux-Robert C: Theophylline toxicity risks and chronic renal failure. Int J Clin Pharmacol 27: 398, 1989
Gulyassy P: Can dialysis remove protein-bound toxins that accumulate due to renal secretory failure? ASAIO J 40: 92, 1994
Gulyassy PF, Depner TA, Shearer GC: Peritoneal versus serum protein binding in CAPD patients. Abstracts Am Soc Artif Organs Meeting, New Orleans, May, 1993, p 91
Schoots AC, Mikkers FEP, Claessens HA, De Smet R, Van Landschoot N, Ringoir S: Characterization of uremic βmiddle molecularβ fractions by gas chromatography, mass spectrometry, isotachophoresis and liquid chromatography. Clin Chem 28: 45, 1982
Vanholder R: Middle molecules as uremic toxins: still a viable hypothesis? Sem Dial 7: 65, 1994
Vanholder R, De Smet R, Hsu C, Vogeleere P, Ringoir S: Uremic toxicity: the middle molecule hypothesis revisited. Sem Nephrol 14: 205, 1994
FΓΌrst P, BergstrΓΆm J, Gordon A, Johnson E, Zimmerman L: Separation of peptides of βmiddleβ molecular weight from biological fluids of patients with uremia. Kidney Int 7: S272, 1975
FΓΌrst P, Zimmerman L, BergstrΓΆm J: Determination of endogenous middle molecules in normal and uremic body fluids. Clin Nephrol 5:178, 1976
De Smet R, Van Landschoot N, Van Der Stiggel G, Ringoir S: Isotachophoresis pattern of LDH inhibiting fractions obtained from uremic ultrafiltrate by gel chromatography. Int J Artif Org 6: 67, 1983
Bultitude FW, Newham SJ: Identification of some abnormal metabolites in plasma from uremic subjects. Clin Cheml 21:1329, 1975
Zimmerman L, FΓΌrst P, BergstrΓΆm J, Jornvall H: A new glycine containing compound with a blocked amino group from uremic body fluids. Clin Nephrol 14: 109, 1980
Gallice P, Monti JP, Crevat A, Durand C, Murisasco A: A compound from uremic plasma and from normal urine isolated by liquid chromatography and identified by nuclear magnetic resonance. Clin Chem 31: 30, 1985
Cueille G, Man NK, Farges JP, Funck-Brentano JL: Characterization of sub-peak b4.2 middle molecule. Artif Organs 4: 28, 1980
Abiko T, Kumikawa M, Ishizaki M, Takahashi H, Sekino H: Identification of a tripeptide in ECUM fluid of an uremic patient. Biophys Bioch Res Com 83: 357, 1978
Abiko T, Kumikawa M, Higuchi H, Sekino H: Identification and synthesis of a heptapeptide in uremic fluid. Biophys Bioch Res Com 84: 184, 1978
Weisshaar G, Brunner H, Friebolin H, Baumann W, Mann H, Opferkuch HJ, Sieberth HG: Isolation of sialylcompounds from hemofiltrate of chronic uremic patients and identification by nuclear magnetic resonance. Adv Exp Med Biol 223: 219, 1987
Klein A, Sarnecka-Keller M, Hanicki Z: Middle sized ninhydrin positive molecules in uremic patients treated by repeated haemodialysis. II. Chief peptide constituents of the fraction. Clin Chim Acta 90: 7, 1978
Gallice P: Toxines urΓ©miques: leur rΓ΄le dans lβinhibition de la pompe sodium chez les patients insuffisants rΓ©naux chroniques traitΓ©s par hΓ©modialyse. ThΓ¨se de doctorat dβΓ©tat, Marseille, 1993
Chapman GV, Ward RA, Farrell PC: Separation and quantification of the middle molecules in uremia. Kidney Int 17: 82, 1980
Faguer P, Man NK, Cueille G, Funck-Brentano JL: Drug interaction in middle molecule analysis, with special reference to acetylsalicyclic acid. Artif Organs 8: 226, 1984
Asaba H, Zimmerman L, BergstrΓΆm J: On drug artifacts in middle molecule analysis. Nephron 39: 73, 1985
Schoots AC, Homan HR, Gladdines MM, Cramers C, De Smet R, Ringoir S: Screening of UV-absorbing solutes in uremic serum by reversed phase HPLC-change of blood levels in different therapies. Clin Chim Acta 146: 37, 1985
Vanholder R, Krause A, De Smet R, Ringoir S: In vivo solute extraction by a new polysulfone membrane with low ultrafiltration capacity. Trans Am Soc Artif Intern Organs 34: 598, 1988
Vanholder RC, De Smet RV, Ringoir SM: Assessment of urea and other uremic markers for quantification of dialysis adequacy. Clin Chem 38: 1429, 1992
Ringoir S, De Smet R, Becaus I: Serum middle molecules in different dialysis strategies. in Aktuelle Probleme der Dialyseverfahren und der Niereninsuffizienz, edited by von Dittrich P, Kopp K, Verlag Bindernagel, Friedburg, 1977, p 128
Haley RJ, Ward DM: Nonenzymatically glucosylated serum proteins in patients with end-stage renal disease. Am J Kidney Dis 8: 115, 1986
FlΓΌckiger R, Harmon W, Meier W, Loo S, Gabbay KH: Hemoglobin carbamylation in uremia. N Engl J Med 304: 823, 1981
Kwan JTC, Carr EC, Neal AD, Burdon J, Raftery MJ, Marsh FP, Barron JL, Bending MR: Carbamylated haemoglobin, urea kinetic modelling and adequacy of dialysis in haemodialysis patients. Nephrol Dial Transplant 6: 38, 1991
Johnson WJ, Hagge WW, Wagoner RD, Dinapoli RP, Rosevaer JW: Effects of urea loading in patients with far-advanced renal failure. Mayo Clin Proc 47: 21, 1972
Scheuer J, Stezoski SW: The effects of uremic compounds on cardiac function and metabolism. J Mol Cell Cardiol 5: 287, 1973
Lowrie EG, Laird NM, Parker TF, Sargent JA: Effect of the hemodialysis prescription on patient morbidity. N Engl J Med 305: 1176, 1980
Owen WF, Lew NL, Liu Y, Lowrie EG, Lazarus JM: The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med 329: 1001, 1993
Lameire NH, Vanholder R, Veyt D, Lambert MC, Ringoir S: A longitudinal, five year survey of urea kinetic parameters in CAPD patients. Kidney Int 42: 426, 1992
Lysaght MJ, Pollock CA, Hallet MD, Ibesl LS, Farrell PC: The relevance of urea kinetic modeling to CAPD. Trans Am Soc Artif Intern Organs 35: 784, 1989
Blake PG, Sombolos K, Abraham G, Weissgarten J, Pemberton R, Chu GL, Oreopoulos DG: Lack of correlation between urea kinetic indices and clinical outcomes in CAPD patients. Kidney Int 39: 700, 1991
Yokozawa T, Fujitsuka N, Oura H: Studies on the precursor of methylguanidine in rats with renal failure. Nephron 58: 90, 1991
Lowrie EG, Lew NL: Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 15: 458, 1990
DzΓΊrik R, LajdovΓ‘ I, SpustovΓ‘ V, Opatrny K: Pseudouridine excretion in healthy subjects and its accumulation in renal failure. Nephron 61: 64, 1992
Daniewska-Michalska D, Motyl T, Geliert R, Kukulska W, Podgurniak M, Opechowska-Pacocha E, Ostrowski K: Efficiency of hemodialysis of pyrimidine compounds in patients with chronic renal failure. Nephron 64: 193, 1993
Giovannetti S, Balestri PL, Barsotti G: Methylguanidine in uremia. Arch Intern Med 131: 709, 1973
Giovannetti S, Barsotti G: Uremic intoxication. Nephron 14: 123, 1975
Minkoff L, Gaertner G, Darab M, Mercier D, Levin ML: Inhibition of brain sodium-potassium ATP-ase in uremic rats. J Lab Clin Med 80: 71, 1972
De Deyn PP, Marescau B, Swartz RD, Hogaerth R, Possemiers I, Lowenthal A: Serum guanidino compound levels and clearances in uremic patients treated with continuous ambulatory peritoneal dialysis. Nephron 54: 307, 1990
Horowitz H, Cohen B, Martinez P, Papayoanou M: Defective ADP-induced platelet factor 3 activation in uremia. Blood 30: 331, 1977
De Deyn P, Maresceau B, Lornoy W, Becaus I, Lowenthal A: Guanidino compounds in uraemic dialysed patients. Clin Chim Acta 157: 143, 1986
De Deyn P, Maresceau B, Lornoy W, Becaus I, Van Leuven I, Van Gorp L, Lowenthal A: Serum guanidino compound levels and the influence of a single hemodialysis in uremic patients undergoing maintenance hemodialysis. Nephron 45: 291, 1987
DβHooge R, Pei YQ, Manil J, De Deyn PP: The uremic guanidino compound guanidinosuccinic acid induces behavioral convulsions and concomitant epileptiform electrocorticographic discharges in mice. Brain Res 598: 326, 1992
Giovannetti S, Barsotti G: Dialysis of methylguanidine. Kidney Int 6: 177, 1974
Boumendil-Podevin EF, Podevin RA, Richet G: Uricosuric agents in uremic sera. Identification of indoxyl sulfate and hippuric acid. J Clin Invest 55: 1142, 1975
Niwa T, Emoto Y, Maeda K, Uehara Y, Yamada N, Shibata M: Oral sorbent suppresses accumulation of albumin-bound indoxyl sulphate in serum of haemodialysis patients. Nephrol Dial Transplant 6: 105, 1991
Niwa T, Takeda N, Tatematsu A, Maeda K: Accumulation of indoxyl sulfate, an inhibitor of drug-binding, in uremic serum as demonstrated by internal-surface reversed-phase liquid chromatography. Clin Chem 34: 2264, 1988
Niwa T, Yazawa T, Kodama T, Uehara Y, Maeda K, Yamada K: Efficient removal of albumin-bound furancarboxylic acid, an inhibitor of erythropoiesis, by continuous ambulatory peritoneal dialysis. Nephron 56: 241, 1990
Clements RS, De Jesus PV, Winegrad AT: Raised plasma myoinositol levels in uraemia experimental neuropathy. Lancet 1: 1137, 1973
Niwa T, Asada H, Maeda K, Yamada K, Ohki T, Saito A: Profiling of organic acids and polyols in nerves of uraemic and non-uraemic patients. J Chromatogr 311: 15, 1986
Niwa T, Sobue G, Maeda K, Mitsuma T: Myoinositol inhibits proliferation of cultured Schwann cells: evidence for neurotoxicity of myoinositol. Nephrol Dial Transplant 4: 662, 1989
Cathcart-Rake W, Porter R, Whittier F, Stein P, Carey M, Grantham J: Effect of diet on serum accumulation and renal excretion of aryl acids and secretory activity in normal and uremic man. Am J Clin Nutr 28: 1110, 1975
Porter RD, Cathcart-Rake WF, Suk Han Wan, Whittier FC, Grantham JJ: Secretory activity and aryl acid content of serum, urine and cerebrospinal fluid in normal and uremic man. J Lab Clin Med 85: 723, 1975
Farrell PC, Gotch FA, Peters JH, Berridge BJ, Lam M: Binding of hippurate in normal plasma and in uremic plasma pre-and post-dialysis. Nephron 20: 40, 1978
Asaba H: Accumulation and excretion of middle molecules. Clin Nephrol 1991: 116, 1983
Zimmerman L, BergstrΓΆm J, JΓΆrnvall H: A method for separation of middle molecules by high performance liquid chromatography: application in studies of glucuronylo-hydroxyhippurate in normal and uremic subjects. Clin Nephrol 25: 94, 1986
Lichtenwalner DM, Byungse S, Lichtenwalner MR: Isolation and chemical characterization of 2-Hydroxybenzoylglycine as a drug binding inhibitor in uremia. J Clin Invest 71: 1289, 1983
Altschule MD, Hegedus ZL: Orthohydroxyhipparic (salicyluric) acid β its physiologic and clinical significance. Clin Pharmacol Ther 15: 111, 1974
Schoots A, Dijkstra JB, Ringoir SMG, Vanholder R, Cramers CA: Are the classical markers sufficient to describe uremic solute accumulation in dialyzed patients? Hippurates reconsidered. Clin Chem 34: 1022, 1988
Vanholder R, Schoots A, Cramers C, De Smet R, Van Landschoot N, Wizemann V, Botella J, Ringoir S: Hippuric acid as a marker, in Uremic Toxins, edited by Ringoir S, Vanholder R, Massry SG, Plenum Press, New York, 1987, p 59
FlΓΆge J, Granolleras C, Shaldon S, Koch KM: Dialysis-associated amyloidosis and beta-2-microglobulin. Contrib Nephrol 61: 27, 1988
Zimmerman L, Egestad B, JΓΆrnvall H, BergstrΓΆm J: Identification and determination of phenylacetylglutamine, a major nitrogenous metabolite in plasma of uremic patients. Clin Nephrol 32: 124, 1989
Zimmerman L, JΓΆrnvall H, BergstrΓΆm J: Phenylacetylglutamine and hippuric acid in uremic and healthy subjects. Nephron 55: 265, 1990
RΓΆhr U, Spiteller G, Tripier D: Isolierung und StrukturaufklΓ€rung der mittelmolekularen Fraktion aus urΓ€mischem HΓ€monltrate. J Liebigβs Ann Chem 96: 881, 1988
Abiko T, Onodera T, Sekino HA: A peptide isolated from the hemodialysate of a uremic patient with immunodeficiency inhibits lymphocyte stimulation. J Appl Biochem 3: 562, 1981
Niese D, Gilsdorf K, Hiester E, Dressen P, Michels S, Dengler HJ: Immunomodulating properties of the uremic pentapeptide H-Asp-Leu-Trp-Glu-Lys-OH in vitro. Klin Wochenschrift 64: 642, 1986
Aronin N, Krieger DT: Plasma immunoreactive beta-endorphin is elevated in uraemia. Clin Endocrinol 18: 459, 1983
Elias AN, Vaziri ND, Maksy M: Plasma beta-endorphin and beta-lipotropin in patients with end-stage renal disease β effects of hemodialysis. Nephron 43: 173, 1986
Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332: 411, 1988
Shichiri M, Hirata Y, Ando K, Emori T, Ohta K, Kimoto S, Ogura M, Inoue A, Marumo F: Plasma endothelin levels in hypertension and chronic renal failure. Hypertension 15: 493, 1990
Brain SD, Williams TJ, Tippins JR, Morris HR, MacIntyre I: Calcitonin gene-related peptide is a potent vasodilator. Nature 313: 54, 1985
Kojima S, Inoue I, Hirata Y, Kimura G, Saito F, Kawano Y, Satani M, Ito K, Omae T: Plasma concentrations of immunoreactive-atrial natriuretic polypeptide in patients on hemodialysis. Nephron 46: 45, 1987
Rascher W, Tulassay T, Lang RE: Atrial natriuretic peptide in plasma of volume-overloaded children with chronic renal failure. Lancet 2: 303, 1985
Niwa T, Fujishiro T, Uema K, Tsuzuki T, Tominaga Y, Emoto Y, Miyazaki T, Maeda K: Effect of hemodialysis on plasma levels of vasoactive peptides: endothelin, calcitonin-gene related peptide and human atrial natriuretic peptide. Nephron 64: 552, 1993
Bazilinski N, Dunea G: Peptidic uremic retention products. Int J Artif Organs 14: 619, 1991
HΓΆrl WH, Haag-Weber M, Georgopoulos A, Block LH: Physicochemical characterization of a polypeptide present in uremic serum that inhibits the biological activity of polymorphonuclear cells. Proc Natl Acad Sci USA 87: 6353, 1990
Haag-Weber M, Mai B, HΓΆrl W: Impaired cellular host defence in peritoneal dialysis by two granulocyte inhibitory proteins. Nephrol Dial Transplant 9: 1769, 1994
Fine A, Cox D, Fontaine B: Elevation of serum phosphate affects parathyroid hormone levels in only 50% of hemodialysis patients, which is unrelated to changes in serum calcium. J Am Soc Nephrol 3: 1947, 1993
Massry SG: Parathyroid hormone: a uremic toxin, in Uremic Toxins, edited by Ringoir S, Vanholder R, Massry SG, Plenum Press, New York, 1987, p 1
Remuzzi G, Dodesini P, Livio M, Mecca G, Benigni A, Schieppati A, Poletti E, de Gaetano G: Parathyroid hormone inhibits human platelet function. Lancet 2: 1321, 1981
Smogorzewski M, Pema AF, Borum PR, Massry SG: Fatty acid oxidation in the myocardium: effects of parathyroid hormone and CRF. Kidney Int 34: 797, 1988
Perna AF, Smogorzewski M, Massry SG. Verapamil reverses PTH-or CRF-induced abnormal fatty acids oxidation in muscle. Kidney Int 34: 774, 1988
Fadda GZ, Thanakitcharu P, Comunale R, Lipson LG, Massry SG: Impaired potassium-induced insulin secretion in chronic renal failure. Kidney Int 40: 413, 1991
Meytes D, Bogin E, Ma A, Dukex PP, Massry SG: Effect of parathyroid hormone on erythropoiesis. J Clin Invest 67: 1263, 1981
Bogin E, Massry SG, Harary I: Effect of parathyroid hormone on rat heart cells. J Clin Invest 67: 1215, 1981
Smogorzewski M, Campese VM, Massry S: Abnormal norepinephrine uptake and release in brain synaptosomes in chronic renal failure. Kidney Int 36: 458, 1989
Ni Z, Smogorzewski M, Massry SG: Derangements in acetylcholine metabolism in brain synaptosomes in chronic renal failure. Kidney Int 44: 630, 1993
Shasha SM, Kristal B, Barzilai M, Makov UE, Shkolnik T: In vitro effect of PTH on normal T cell functions. Nephron 50: 212, 1988
Alexiewicz JM, Klinger M, Pitts TO, Gacoing Z, Linker-Israeli M, Massry SG: Parathyroid hormone inhibits B cell proliferation: implications in chronic renal failure. J Am Soc Nephrol 1: 236, 1990
Perna AF, Smogorzewski M, Massry SG: Effects of verapamil on the abnormalities in fatty acid oxidation of myocardium. Kidney Int 36: 453, 1989
DβAmour P, Jobin J, Hamel L, LβEcuyer N: iPTH values during hemodialysis: role of ionized Ca, dialysis membranes and iPTH assays. Kidney Int 38: 308, 1990
Vincent C, Revillard JP, Galland M, Traeger J: Serum beta-2-microglobulin in hemodialyzed patients. Nephron 21:260, 1978
Sargent JA, Gotch FA: Principles and biophysics of dialysis, in Replacement of Renal Function by Dialysis, edited by Maher JF, Kluwer Academic, Dordrecht, 1989, p 87
Shirahama T, Skinner M, Cohen AS, Gejyo F, Arakawa M, Suzuki M, Hirasawa Y: Histochemical and immuno-histochemical characterization of amyloid associated with chronic hemodialysis as beta-2-microglobulin. J Lab Invest 53: 705, 1985
Gejyo F, Odani S, Yamada T, Honma N, Saito H, Suzuki Y, Nakagawa Y, Kobayashi H, Maruyama Y, Hirasawa Y, Suzuki M, Arakawa M: Beta-2-microglobulin: a new form of amyloid protein associated with chronic hemodialysis. Kidney Int 30: 385, 1986
Hauglustaine D, Waer M, Michielsen P, Goebels J, Vandeputte M: Haemodialysis membranes, serum beta-2-microglobulin, and dialysis amyloidosis. Lancet 1: 1211, 1986 (Letter)
Vanholder RC, Ringoir SM: Intradialytic body weight changes and dialyzer pore size as main contributing factors to the evolution of beta-2-microglobulin in dialysis. Blood Purif 8: 32, 1990
Petersen J, Moore RM, Kaczmarek RG, Singh B, Yeh I, Hamburger S, Kankam M: The effects of reprocessing cuprophane and polysulfone dialyzers on Ξ²2-microglobulin removal from hemodialysis patients. Am J Kidney Dis 17: 174, 1991
van Ypersele de Strihou C, Jadoul M, Malghem J, Maldague B, Jamart J: Effect of dialysis membrane and patientβs age on signs of dialysis-related amyloidosis. Kidney Int 39: 1012, 1991
Gagnon RF, Somerville P, Thomson DM: Circulating form of beta-2-microglobulin in dialysis patients. Am J Nephrol 8: 379, 1988
Renaud H, Fournier A, Morinière Ph, Westeel PF, El Esper N, Belbrik S, Marie A, Cohen-Solal HE, Sebert JL: Erosive osteoarthropathy associated with β2-microglobulin amyloidosis in a uremic patient treated exclusively by long-term hemofiltration with biocompatible membranes. Nephrol Dial Transplant 3: 820, 1988
Campbell RA: Polyamines and uremia, in Uremic Toxins, edited by Ringoir S, Vanholder R, Massry SG, Plenum Press, New York, 1987, p 47
Simmonds HA, Cameron JS, Morris GS, Fairbanks LD, Davies PM: Purine metabolites in uraemia, in Uremic Toxins, edited by Ringoir S, Vanholder R, Massry SG, Plenum Press, New York, 1987, p 73
Hsu CH, Patel S, Vanholder R: Effect of uric acid on plasma levels of calcitriol in renal failure. J Am Soc Nephrol 4: 1035, 1993.
Gerrits GPMJ, Monnens LAH, De Abreu RA, SchrΓΆder CH, Trijbels JMF, Gabreels, FJM: Disturbances of cerebral purine and pyrimidine metabolism in young children with chronic renal failure. Nephron 58: 310, 1991
Ludwig GD, Senesky D, Bluemle LW, Elkinton JR: Indoles in uremia: identification by countercurrent distribution and paper chromatography. Am J Clin Nutr 21:436, 1968
Wengle B, HellstrΓΆm K: Volatile phenols in serum of uraemic patients. Clin Science 43: 493, 1972
Wardle EN, Wilkinson K: Free phenols in chronic renal failure. Clin Nephrol 6: 361, 1976
Niwa T, Maeda K, Ohki T, Saito A, Kobayashi K: A gas chromatographic-mass spectrometric analysis for phenols in uremic serum. Clin Chim Acta 110: 51, 1981
Hicks JM, Young DS, Wootton IDP: The effect of uraemic blood constituents on certain cerebral enzymes. Clin Chim Acta 9: 228, 1964
Rabiner SF, Molinas F: The role of phenol and phenolic acids on the thrombocytopathy and defective platelet aggregation of patients with renal failure. Am J Med 49: 346, 1970
Lascelles PT, Taylor WH: The effect upon tissue respiration in vitro of metabolites which accumulate in uraemic coma. Clin Science 31: 403, 1966
Wardle EN, Williams R: Polymorph leukocyte function in uraemia and jaundice. Acta Haemat 64: 157, 1980
Turner GA, Wardle EN: Effect of unconjugated and conjugated phenol and uraemia on the synthesis of adenosine 3β:5βcyclic monophosphate in rat brain homogenates. Clin Science Mot Med 55: 271, 1978
Vanholder R, De Smet R, Waterloos MA, Van Landschoot N, Ringoir S: Characterization of p-cresol and phenol as uremic toxins inhibiting polymorphonuclear (PMNL) respiratory burst response to phagocytosis. J Am Soc Nephrol 4: 786, 1993 (Abstract)
Wardle EN: Chemiluminescence and Superoxide anions generated by phagocytes in uraemia. Nephron 40: 37D, 1985 (Letter)
Battling D, Seedorf M, Mithofer A, Weiler EW: Cloning and expression of an Arabidopsis nitrilase which can convert indole-3-acetonitrile to the plant hormone, indole-3-acetic acid. Eur J Biochem 205: 417, 1992
Efimov S, Shevehenko V, Shchukin I, Preobrazhenskaya M: The influence of 1β-methyl-and 1β-ethylascorbigen on metabolism of arachidonic acid in murine spleen cells. Biochem Biophys Res Commun 190: 895, 1993
Suto A, Bradlow HL, Wong GY, Osborne MP, Telang NT: Persistent estrogen responsiveness of res oncogene-transformed mouse mammary epithelial cells. Steroids 57: 262, 1992
Wallaeys B, Cornelis R, Mees L, Lameire N: Trace elements in serum, packed cells and dialysate in CAPD patients. Kidney Int 30: 599, 1986
Van Renterghem D, Cornelis R, Vanholder R: Behaviour of 12 trace elements in serum of uremic patients on hemodiafiltration. J Trace Elem Electrolytes Health Dis 6: 169, 1992
De Kimpe J, Cornelis R, Mees L, Van Lierde S, Vanholder R: More than tenfold increase of arsenic in serum and packed cells of chronic hemodialysis patients. Am J Nephrol 13: 429, 1993
Mahajan SK: Zinc metabolism in uremia. Int J Artif Organs 11: 223, 1988
Cornelis R, Ringoir S, Lameire N, Mees L, Hoste J: Blood bromine in uremic patients. Min Electrol Metab 2: 186, 1979
Cornelis R, Mees L, Ringoir S, Hoste J: Serum and red blood cell Zn, Se, Cs and Rb in dialysis patients. Min Electrol Metab 2: 88, 1979
Van Renterghem D, Cornelis R, Mees L, Vanholder R: The effect of adding Br and Zn supplements to the dialysate on the concentrations of Br and Zn in the blood of hemodialyzed patients. J Trace Elem Electrolytes Health Dis 6: 105, 1992
Sugisaki H, Onohara M, Kunimoto T: Dynamic behavior of plasma phosphate in chronic dialysis patients. Trans Am Soc Artif Intern Organs 28: 302, 1982
Haas T, Hillion D, Dongradi G: Phosphate kinetics in dialysis patients. Nephrol Dial Transplant 6(Suppl 2): 108, 1991
Takeda N, Niwa T, Tatematsu A, Suzuki M: Identification and quantification of a protein-bound ligand in uremic serum. Clin Chem 33: 682, 1987
Mabuchi H, Nakahashi H: A major endogenous ligand substance involved in renal failure. Nephron 49: 277, 1988
Mabuchi H, Nakahashi H: Inhibition of hepatic glutathione S-transferases by a major endogenous ligand substance present in uremic serum. Nephron 49: 281, 1988
Niwa T, Aiuchi T, Nakaya K, Emoto Y, Miyazaki T, Maeda K: Inhibition of mitochondria! respiration by furancarboxylic acid accumulated in uremic serum in its albumin-bound and non-dialyzable form. Clin Nephrol 39: 92, 1993
Rutten GA, Schoots AC, Vanholder R, De Smet R, Ringoir S, Cramers CA: Hexachlorobenzene and 1,1-di(4-chlorophenyl)-2,2-dichloroethene in serum of uremic patients and healthy persons: determination by capillary gas chromatography and electron capture detection. Nephron 48: 217, 1988
Manabe S, Yanagisawa H, Ishikawa S, Kitagawa Y, Kanai Y, Wada O: Accumulation of 2-amino-6-methyldipyrido(1,2-a: 3,β 2-β-d)imidazole and 2-aminodipyrido(1,2-a:3β,-2β-d)imidazole, carcinogenic glutamic acid pyrolysis products, in plasma of patients with uremia. Cancer Res 47: 6150, 1987
Turney JH, Davison AM, Forbes MA, Cooper EH: Hyaluronic acid in end-stage renal failure treated by haemodialysis: clinical correlates and implications. Nephrol Dial Transplant 6: 566, 1991
del Castillo E, Fuenzalida R, Uranga J: Increased glomerular filtration rate and glomerulopressin activity in diabetic dogs. Harm Metab Res 9: 46, 1975
Zhou XJ, Vaziri ND, Kaupke CJ: Effects of chronic renal failure and hemodialysis on plasma glomerulopressin. Int J Artif Organs 16: 180, 1993
Alvestrand A, BergstrΓΆm J: Glomerular hyperfiltration and protein ingestion, during glucagon infusion, and in insulin-dependent diabetes is induced by a liver hormone: deficiency production of this hormone in hepatic failure causes hepatorenal syndrome. Lancet 1: 195, 1984
Garcia-OcaΓ±a A, Ortega J, GonzΓ‘lez-GarcΓa Y, GarcΓa-CantΓ³n C, Esbrit P: Partial purification of a renotropic activity from plasma of uninephrectomized human subjects. Nephron 64: 547, 1993
Costello JF, Sadovnic MJ, Cottington EM: Plasmaoxalate levels rise in hemodialysis patients despite increased oxalate removal. J Am Soc Nephrol 1: 1289, 1991
Gallice PM, Monti JP, Braguer DL, Baz M, Elsen RE, Berland YF, Crevat AD: Ascorbic acid derivatives in two different fractions of uremic toxins. Int J Artif Organs 14: 754, 1991
Cailleux A, Subra JF, Riberi P, Allain P: Uptake of tri-halomethanes by patients during hemodialysis. Clin Chim Acta 181: 75, 1989
Vallance P, Leone A, Calver A, Collier J, Moncada S: Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339: 572, 1992
Remuzzi G, Perico N, Zoja C, Corna D, Macconi D, ViganΓΆ GL: Role of endothelium-derived nitric oxide in the bleeding tendency of uremia. J Clin Invest 86: 1768, 1990
Lipton SA, Choi YB, Pan ZH, Lei SZ, Chen HSV, Sucher NJ, Loscalzo J, Singel DJ, Stamler JS: A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds. Nature 364: 626, 1993
Ihle BU, Cox RW, Dunn SR, Simenhoff ML: Determination of body burden of uremic toxins. Clin Nephrol 22: 82, 1984
Maxfield FR, Willingham MC, Davies PJ, Pastan I: Amines inhibit the clustering of Ξ±-macroglobulin and EGF on the fibroblast cell surface. Nature 277: 661, 1979
Pascual M: Le facteur D du complΓ©ment: toxine urΓ©mique? NΓ©phrologie 12: 215, 1991
Pascual M, Schifferli JA: Adsorption of complement factor D by polyacrylonitrile dialysis membranes. Kidney Int 43: 903, 1992
Vaziri ND, Oveisi F, Wierzbiezki M, Shaw V, Sporty LD: Serum melatonin and 6-sulfatoxymelatonin in end-stage renal disease: effect of hemodialysis. Artif Organs 17: 764, 1993
Witko V, Nguyen AT, Descamps-Latscha B: Microtiter plate assay for phagocyte-derived taurine-catecholamines. J Clin Lab Anal 6: 47, 1993
Thomas EL, Grisham MB, Jefferson MM: Myeloperoxidase-dependent effect of amines on functions of isolated neutrophils. J Clin Invest 72: 441, 1983
Chauveau P, Chadefaux B, Coude M, Aupetit J, Hannedouche T, Kamoun P, Jungers P: Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients. Kidney Int 43: S72, 1993
Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, Graham I: Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 324: 1149, 1991
Schools A, Mikkers F, Cramers C, De Smet R, Ringoir S: Uremic toxins and the elusive middle molecules. Nephron 38: 1, 1984
Vanholder R, Ringoir S: Adequacy of dialysis: a critical analysis. Editorial review. Kidney Int 42: 540, 1992
Goldman M, Lagmiche M, Dhaene M, Amraoui Z, Thayse C, Vanherweghem JL: Adsorption of Ξ²2microglobulin on dialysis membranes: comparison of different dialyzers and effects of reuse procedures. Int J Artif Organs 12: 373, 1989
Shemesh O, Golbetz H, Kriss JP, Myers BD: Limitations of creatinine as a filtration marker in glomerulopathic patients. Kidney Int 28: 830, 1985
Sargent JA, Gotch FA: Mathematic modeling of dialysis therapy. Kidney Int 18: S2, 1980
Vanholder R, Hoenich N, Ringoir S: Adequacy studies of fistula single-needle dialysis. Am J Kidney Dis 10: 417, 1987
Borah MF, Schoenfeld PY, Gotch FA, Sargent JA, Wolfson M, Humphreys MH: Nitrogen balance during intermittent dialysis therapy of uremia. Kidney Int 14: 491, 1978
Buur T, Timpka T, Lundberg M: Urea kinetics and clinical evaluation of the haemodialysis patient. Nephrol Dial Transplant 5: 347, 1990
Watson PE, Watson ID, Batt RD: Total body water volumes for adult males and females estimated from simple anthropometric measurements. Am J Clin Nutr 33: 27, 1980
Malchesky PS, Ellis P, Nosse G, Magnusson M, Lankhorst B, Nakmoto S: Direct quantification of dialysis. Dial Transplant 11: 42, 1982
Vanholder R, Van Trimpont P, Ringoir S: Urea kinetic modelling: comparison of three methods. J Med Engin Technol 13: 87, 1989
Keshaviah P, Collins A: A re-appraisal of the National Cooperative Dialysis Study (NCDS). Kidney Int 33: 227 1988 (Abstract)
Shen FH, Hsu KT: Lower mortality and morbidity associated with higher Kt/V in hemodialysis patients. J Am Soc Nephrol 1: 377, 1990 (Abstract)
Hakim RM, Fearon DT, Lazarus JM: Biocompatibility of dialysis membranes: effects of chronic complement activation. Kidney Int 26: 194, 1984
Gutierrez A, Alvestrand A, Wahren J, BergstrΓΆm J: Effect of in vivo contact between blood and dialysis membranes on protein catabolism in humans. Kidney Int 38: 487, 1990
Lindsay RM, Spanner E: A hypothesis: the protein catabolic rate is dependent upon the type and amount of treatment in dialyzed uremic patients. Am J Kidney Dis 13: 382, 1989
Sargent JA: Shortfalls in the delivery of dialysis. Am J Kidney Dis 15:500, 1990
Ellis PW, Malchesky PS, Magnusson MO, Goormastic M, Nakamoto S: Comparison of two methods of kinetic modeling. Trans Am Soc Artif Intern Organs 30: 60, 1984
Ilstrup K, Hanson G, Shapiro W, Keshaviah P: Examining the foundations of urea kinetics. Trans Am Soc Artif Intern Organs 31: 164, 1985
Aebischer P, Schorderet D, Juillerat A, Wauters JP, Fellay G: Comparison of urea kinetics and direct dialysis quantification in hemodialysis patients. Trans Am Soc Artif Intern Organs 31: 164, 1985
Hoenich NA, Keir MJ, Hildreth K, Woffindin C, Goodall R, Vanholder R, Ward MK: Urea kinetic modeling: comparing the options. Artif Organs 17: 813, 1993
Stange J, Ramlow W, Mitzner S, Schmidt R, Klinkmann H: Dialysis against a recycled albumin solution enables the removal of albumin-bound toxins. Artif Organs 17: 809, 1993
Veech RL: The untoward effects of the anions of dialysis fluids. Kidney Int 34: 587, 1988
Chiu WY, Yamada K, Saito A, Ogawa H, Takagi T, Chung TG: Comparison of serum protein removal in haemodialysis therapy by partly protein-permeable haemodialysers. J Chromatogr 428: 25, 1988
Vanholder R, De Smet R, Schoots A, Ringoir S: Correlation of a colorimetric and a HPLC method for the determination of serum hippuric acid concentrations in uremia. Nephron 49: 164, 1988
Niwa T, Ise M, Miyazaki T, Maeda K: Suppressive effect of an oral sorbent on the accumulation of p-cresol in the serum of experimental uremic rats. Nephron 65: 82, 1993
Author information
Authors and Affiliations
Editor information
Rights and permissions
Copyright information
Β© 1996 Kluwer Academic Publishers
About this chapter
Cite this chapter
Vanholder, R., De Smet, R., Vogeleere, P., Hsu, C., Ringoir, S. (1996). The Uraemic Syndrome. In: Jacobs, C., Kjellstrand, C.M., Koch, K.M., Winchester, J.F. (eds) Replacement of Renal Function by Dialysis. Springer, Dordrecht. https://doi.org/10.1007/978-0-585-36947-1_1
Download citation
DOI: https://doi.org/10.1007/978-0-585-36947-1_1
Publisher Name: Springer, Dordrecht
Print ISBN: 978-0-7923-3610-5
Online ISBN: 978-0-585-36947-1
eBook Packages: Springer Book Archive